Skip to main content

Ranitidine improves lymphocyte function after severe head injury: results of a randomized, double-blind study.

Publication ,  Journal Article
Rixen, D; Livingston, DH; Loder, P; Denny, TN
Published in: Crit Care Med
November 1996

OBJECTIVE: To study the immunomodulatory effect of the histamine receptor antagonist, ranitidine, in patients admitted to the intensive care unit after severe head injury. DESIGN: Randomized, prospective, double-blind study. SETTING: Surgical intensive care unit of a university Level I trauma center. PATIENTS: Twenty patients admitted with a Glasgow Coma Scale score of < 10 who were enrolled as part of a prospective, multicenter trial to assess the impact of multiple risk factors and ranitidine prophylaxis on the development of stress-related upper gastrointestinal bleeding. INTERVENTIONS: Continuous infusion of ranitidine at 6.25 mg/hr (n = 9) or placebo (n = 11) for a maximum of 5 days. MEASUREMENTS AND MAIN RESULTS: Before the patients were enrolled in the study and on completion of treatment, lymphocyte cell-surface antigen expression was determined by flow cytometry (n = 14 patients); mitogen-stimulated interferon-gamma and interleukin-2 production were measured by enzyme-linked immunosorbent assay (n = 19 patients). Treatment with ranitidine, but not placebo, was associated with a significant increase in CD4+ lymphocytes (33% to 49%; p < .05) and a significant decrease in CD8+ lymphocytes (41% to 27%; p < .05). Also, the mitogen-stimulated interferon-gamma production increased from 121 to 269 pg/mL (p < .05) in patients treated with ranitidine, but not in patients treated with placebo. There were no significant differences in interleukin-2 production or circulating B-cell concentrations between both groups. CONCLUSION: This study demonstrates an immunostimulatory effect of the histamine-2-receptor antagonist, ranitidine, both at the cellular and mediator levels in patients after head injury.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Crit Care Med

DOI

ISSN

0090-3493

Publication Date

November 1996

Volume

24

Issue

11

Start / End Page

1787 / 1792

Location

United States

Related Subject Headings

  • Ranitidine
  • Prospective Studies
  • Middle Aged
  • Male
  • Interferon-gamma
  • Injury Severity Score
  • Infusions, Intravenous
  • Humans
  • Histamine H2 Antagonists
  • Glasgow Coma Scale
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rixen, D., Livingston, D. H., Loder, P., & Denny, T. N. (1996). Ranitidine improves lymphocyte function after severe head injury: results of a randomized, double-blind study. Crit Care Med, 24(11), 1787–1792. https://doi.org/10.1097/00003246-199611000-00005
Rixen, D., D. H. Livingston, P. Loder, and T. N. Denny. “Ranitidine improves lymphocyte function after severe head injury: results of a randomized, double-blind study.Crit Care Med 24, no. 11 (November 1996): 1787–92. https://doi.org/10.1097/00003246-199611000-00005.
Rixen D, Livingston DH, Loder P, Denny TN. Ranitidine improves lymphocyte function after severe head injury: results of a randomized, double-blind study. Crit Care Med. 1996 Nov;24(11):1787–92.
Rixen, D., et al. “Ranitidine improves lymphocyte function after severe head injury: results of a randomized, double-blind study.Crit Care Med, vol. 24, no. 11, Nov. 1996, pp. 1787–92. Pubmed, doi:10.1097/00003246-199611000-00005.
Rixen D, Livingston DH, Loder P, Denny TN. Ranitidine improves lymphocyte function after severe head injury: results of a randomized, double-blind study. Crit Care Med. 1996 Nov;24(11):1787–1792.

Published In

Crit Care Med

DOI

ISSN

0090-3493

Publication Date

November 1996

Volume

24

Issue

11

Start / End Page

1787 / 1792

Location

United States

Related Subject Headings

  • Ranitidine
  • Prospective Studies
  • Middle Aged
  • Male
  • Interferon-gamma
  • Injury Severity Score
  • Infusions, Intravenous
  • Humans
  • Histamine H2 Antagonists
  • Glasgow Coma Scale